{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}],"title":"60"},{"measurements":[{"groupId":"OG000","value":"14"}],"title":"180"},{"measurements":[{"groupId":"OG000","value":"19"}],"title":"540"},{"measurements":[{"groupId":"OG000","value":"10"}],"title":"1620"},{"measurements":[{"groupId":"OG000","value":"11"}],"title":"4860"},{"measurements":[{"groupId":"OG000","value":"7"}],"title":"14580"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"131220"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"}],"units":"Participants"}],"description":"Serum samples were assayed for ADA using a validated analytical method. Number of ADA ever positive participants for each serum of ADA titer (60, 180, 540, 1620, 4860, 14580, and 131220) are reported.","groups":[{"description":"Participants received an intravenous (IV) infusion of 10 milligrams per kilograms (mg/kg) of Avelumab along with BSC, on Day 1 and 15 of each 28 days treatment cycle, until confirmed disease progression, participant refusal, lost to follow up, unacceptable toxicity, or study termination by the sponsor, whichever occurred first. BSC was administered as per the treating physician. Participants were followed up until death, end of the study or withdrawal of consent, whichever comes first, regardless of initiation of new anti-cancer therapy.","id":"OG000","title":"Avelumab + Best Supportive Care (BSC)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The immunogenicity analysis set included participants who had received at least one dose of study drug and who had ADA ever-positive results. Here \"Overall number of participants analyzed\" signifies participants who had data available for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From randomization up to the 30-Day Follow-up visit (maximum duration of up to approximately 68 months)","title":"Number of ADA Ever Positive Participants For Each Serum of ADA Titers for Avelumab","type":"SECONDARY","unitOfMeasure":"Participants"}